TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Childhood Obesity - Programming by Infant Nutrition
Brief Summary: Primary hypothesis to be tested:

Early protein intake predicts infant growth and later risk of childhood obesity.

* Childhood obesity is a major public health problem and is an identified priority concern for the health care. Infants fed formula are more likely to become obese than breastfed infants. The higher protein content of infant formulae, compared with breast milk, could be a causal factor.
* The study will in a multicentre intervention trial on newborn infants investigate whether feeding infant formulae, which differ in their level of milk proteins, can influence the risk of later childhood obesity. The trial will take place in five countries with different habitual total protein intakes to increase the range of protein intakes
* The investigators will study body composition, hormonal status, protein metabolism and anthropometric markers of childhood obesity. The whole cohort will be followed up until age 18 years, to assess the long term impact on the prevalence of obesity.
* The investigators will explore the impact of consumer (parental) attitudes to, and perceptions of, different practices of infant feeding in relation to infant behaviour (satisfaction, crying, sleep duration). This consumer science information will help improve the understanding of consumer (infants and parents) acceptance of and preference for foods that contribute to healthy diets.
* If a relationship between early dietary protein intake and later childhood obesity risk is confirmed, it offers possibilities for the prevention of obesity, for improving advice given to parents and for developing nutritionally improved dietary products for infants.


Options:
A: Arm Label: Active video game play; Type: EXPERIMENTAL; Interventions: Behavioral: Active video game play | Intervention Type: BEHAVIORAL; Name: Active video game play; Assigned to Arm(s): Active video game play
B: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Challenge! | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Challenge!; Assigned to Arm(s): Intervention group
C: Intervention Type: BEHAVIORAL; Name: To change structure and roles of primary care teams to optimize prevention of obesity; Assigned to Arm(s): N/A
D: Arm Label: Lower protein formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lower protein formula; Higher protein formula | Arm Label: Higher protein formula; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Lower protein formula; Higher protein formula | Arm Label: Breastfed reference group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Lower protein formula; Higher protein formula; Assigned to Arm(s): Higher protein formula, Lower protein formula

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Efficacy And Safety Study Of Sunitinib Malate (SU011248) Administered In A Continuous Daily Regimen In Patients With Advanced (First-Line) Renal Cell Cancer
Brief Summary: A phase II study to allow patients with advanced kidney cancer access to sunitinib malate treatment and to find out the good and bad effects of taking 37.5 mg sunitinib malate in a continuous daily regimen (once per day) for one year.


Options:
A: Arm Label: Immediate nephrectomy; Type: ACTIVE_COMPARATOR; Interventions: Genetic: gene expression analysis, Other: biologic sample preservation procedure, Other: laboratory biomarker analysis, Procedure: therapeutic conventional surgery | Arm Label: Deferred nephrectomy; Type: EXPERIMENTAL; Interventions: Procedure: timing of surgery, Genetic: gene expression analysis, Other: biologic sample preservation procedure, Other: laboratory biomarker analysis | Intervention Type: PROCEDURE; Name: timing of surgery; Assigned to Arm(s): Deferred nephrectomy | Intervention Type: GENETIC; Name: gene expression analysis; Assigned to Arm(s): Deferred nephrectomy, Immediate nephrectomy | Intervention Type: OTHER; Name: biologic sample preservation procedure; Assigned to Arm(s): Deferred nephrectomy, Immediate nephrectomy | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): Deferred nephrectomy, Immediate nephrectomy | Intervention Type: PROCEDURE; Name: therapeutic conventional surgery; Assigned to Arm(s): Immediate nephrectomy
B: Arm Label: A; Type: OTHER; Interventions: Drug: axitinib | Arm Label: B; Type: OTHER; Interventions: Drug: axitinib | Arm Label: C; Type: OTHER; Interventions: Drug: axitinib | Intervention Type: DRUG; Name: axitinib; Assigned to Arm(s): A | Intervention Type: DRUG; Name: axitinib; Assigned to Arm(s): B | Intervention Type: DRUG; Name: axitinib; Assigned to Arm(s): C
C: Arm Label: SUNITINIB MALATE.; Type: EXPERIMENTAL; Interventions: Drug: Sunitinib malate | Intervention Type: DRUG; Name: Sunitinib malate; Assigned to Arm(s): SUNITINIB MALATE.
D: Arm Label: Arm I (cabozantinib-s-malate); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cabozantinib S-malate, Other: Laboratory Biomarker Analysis | Arm Label: Arm II (sunitinib malate); Type: ACTIVE_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Drug: Sunitinib Malate | Intervention Type: DRUG; Name: Cabozantinib S-malate; Assigned to Arm(s): Arm I (cabozantinib-s-malate) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (cabozantinib-s-malate), Arm II (sunitinib malate) | Intervention Type: DRUG; Name: Sunitinib Malate; Assigned to Arm(s): Arm II (sunitinib malate)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cognitive Behavioral Skills Training for Schizophrenia
Brief Summary: This study evaluated the effectiveness of Cognitive Behavioral Social Skills Training versus goal-focused supportive contact in improving social functioning in people with schizophrenia.


Options:
A: Intervention Type: BEHAVIORAL; Name: Integrated treatment, family involvement; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Social skills training; Assigned to Arm(s): N/A
B: Arm Label: Individual Placement and Support; Type: EXPERIMENTAL; Interventions: Behavioral: Individual Placement and Support | Arm Label: Ordinary employment schemes; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Ordinary employment schemes | Intervention Type: BEHAVIORAL; Name: Individual Placement and Support; Assigned to Arm(s): Individual Placement and Support | Intervention Type: BEHAVIORAL; Name: Ordinary employment schemes; Assigned to Arm(s): Ordinary employment schemes
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Social Skills Training (CBSST), Behavioral: Social Skills Training, Behavioral: Goal Setting | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Goal-focused supportive contact (GFSC), Behavioral: Goal Setting | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Social Skills Training (CBSST); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Goal-focused supportive contact (GFSC); Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Social Skills Training; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Goal Setting; Assigned to Arm(s): 1, 2
D: Intervention Type: PROCEDURE; Name: Individual placement and support (vocational rehabilitation); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Brief Summary: The purpose of this study is to determine the safety of and immune response to a new human papillomavirus (HPV) vaccine in HIV (Human immunodeficiency virus) infected children between the ages of 7 and 12 years.


Options:
A: Arm Label: Quadrivalent HPV Vaccine; Type: EXPERIMENTAL; Interventions: Biological: Quadrivalent HPV Vaccine | Arm Label: Placebo Vaccine; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo Vaccine for Male Participants Only, Biological: Placebo Vaccine for Female Participants Only | Intervention Type: BIOLOGICAL; Name: Quadrivalent HPV Vaccine; Assigned to Arm(s): Quadrivalent HPV Vaccine | Intervention Type: BIOLOGICAL; Name: Placebo Vaccine for Male Participants Only; Assigned to Arm(s): Placebo Vaccine | Intervention Type: BIOLOGICAL; Name: Placebo Vaccine for Female Participants Only; Assigned to Arm(s): Placebo Vaccine
B: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix vaccine | Arm Label: Engerix-B Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Engerix-B vaccine | Intervention Type: BIOLOGICAL; Name: Cervarix vaccine; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Engerix-B vaccine; Assigned to Arm(s): Engerix-B Group
C: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix™ | Arm Label: Havrix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Havrix™-based investigational formulation | Intervention Type: BIOLOGICAL; Name: Cervarix™; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Havrix™-based investigational formulation; Assigned to Arm(s): Havrix Group
D: Arm Label: Arm A: QHPV; Type: ACTIVE_COMPARATOR; Interventions: Biological: Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV) | Arm Label: Arm B: Placebo/QHPV; Type: OTHER; Interventions: Other: Placebo/QHPV | Intervention Type: BIOLOGICAL; Name: Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV); Assigned to Arm(s): Arm A: QHPV | Intervention Type: OTHER; Name: Placebo/QHPV; Assigned to Arm(s): Arm B: Placebo/QHPV

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cognitive Training and Enhanced Supported Employment
Brief Summary: This study will evaluate the effectiveness of a computer-based cognitive enhancement program plus a work therapy program at improving productivity, work performance, and quality of life in schizophrenic individuals.


Options:
A: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Family-aided Assertive Community Treatment; Type: EXPERIMENTAL; Interventions: Drug: aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine, Behavioral: Psychoeducational multifamily group treatment, Behavioral: Supported employment and education | Intervention Type: DRUG; Name: aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine; Assigned to Arm(s): Family-aided Assertive Community Treatment | Intervention Type: BEHAVIORAL; Name: Psychoeducational multifamily group treatment; Assigned to Arm(s): Family-aided Assertive Community Treatment | Intervention Type: BEHAVIORAL; Name: Supported employment and education; Assigned to Arm(s): Family-aided Assertive Community Treatment
B: Arm Label: ACT + CBSST; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Social Skills Training (CBSST) | Arm Label: ACT only; Type: ACTIVE_COMPARATOR; Interventions: Other: Assertive Community Treatment (ACT) | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Social Skills Training (CBSST); Assigned to Arm(s): ACT + CBSST | Intervention Type: OTHER; Name: Assertive Community Treatment (ACT); Assigned to Arm(s): ACT only
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Social Skills Training (CBSST), Behavioral: Social Skills Training, Behavioral: Goal Setting | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Goal-focused supportive contact (GFSC), Behavioral: Goal Setting | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Social Skills Training (CBSST); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Goal-focused supportive contact (GFSC); Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Social Skills Training; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Goal Setting; Assigned to Arm(s): 1, 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Computer-Based Cognitive Enhancement Training Program, Behavioral: Work Therapy Program | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Work Therapy Program | Intervention Type: BEHAVIORAL; Name: Computer-Based Cognitive Enhancement Training Program; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Work Therapy Program; Assigned to Arm(s): 1, 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter Phase 3 Study to Compare the Efficacy of Panitumumab in Combination With Chemotherapy to the Efficacy of Chemotherapy Alone in Patients With Previously Treated Metastatic Colorectal Cancer
Brief Summary: The purpose of this study is to evaluate the treatment effect of panitumumab plus FOLFIRI compared to FOLFIRI alone as second line therapy for metastatic colorectal cancer.


Options:
A: Intervention Type: DRUG; Name: ABX-EGF; Assigned to Arm(s): N/A
B: Arm Label: bevacizumab and erlotinib (KRAS WT); Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab, erlotinib | Arm Label: bevacizumab (KRAS WT); Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab | Arm Label: bevacizumab (KRAS mutated); Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab | Arm Label: low dose capecitabine (KRAS mutated); Type: ACTIVE_COMPARATOR; Interventions: Drug: low dose capecitabine | Intervention Type: DRUG; Name: bevacizumab, erlotinib; Assigned to Arm(s): bevacizumab and erlotinib (KRAS WT) | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): bevacizumab (KRAS WT) | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): bevacizumab (KRAS mutated) | Intervention Type: DRUG; Name: low dose capecitabine; Assigned to Arm(s): low dose capecitabine (KRAS mutated)
C: Arm Label: Panitumumab Plus FOLFIRI; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab, Drug: FOLFIRI | Arm Label: FOLFIRI Alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: FOLFIRI | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): Panitumumab Plus FOLFIRI | Intervention Type: DRUG; Name: FOLFIRI; Assigned to Arm(s): FOLFIRI Alone, Panitumumab Plus FOLFIRI
D: Arm Label: Cetuximab Plus FOLFIRI; Type: EXPERIMENTAL; Interventions: Drug: Cetuximab, Drug: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan) | Arm Label: FOLFIRI Alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan) | Intervention Type: DRUG; Name: Cetuximab; Assigned to Arm(s): Cetuximab Plus FOLFIRI | Intervention Type: DRUG; Name: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan); Assigned to Arm(s): Cetuximab Plus FOLFIRI, FOLFIRI Alone

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*5701) for Susceptibility to Abacavir Hypersensitivity
Brief Summary: Study to evaluate the utility of prospective HLA-B\*5701 screening on the incidence of abacavir hypersensitivity (ABC HSR) in 1800 previously ABC-naive adults with HIV-1 from Europe, Australia and other countries as applicable. The study has two (co-primary) objectives: i) to determine if screening for HLA-B\*5701 prior to ABC-containing HAART results in a lower incidence of clinically-suspected HSR versus current standard of care (no genetic screening) and ii) to determine if screening for HLA-B\*5701 prior to ABC-containing HAART, results in a significantly lower incidence of immunologically-confirmed HSR versus current standard of care (no genetic screening or patch testing). The study consists of up to a 28-day screening period, a randomised observation period (Day 1 through Week 6) and, for subjects experiencing a suspected ABC HSR and a subset of ABC-tolerant subjects, an epicutaneous patch test (EPT) assessment period. Eligible subjects will be randomised to one of two study arms: a Current Standard of Care Arm (no prospective genetic screening: Control) and a Genetic Screening Arm (prospective genetic screening). Subjects identified as HLA-B\*5701 positive in the prospective Genetic Screening Arm will not receive ABC and will be excluded from further study. Subjects who experience suspected ABC HSR during the 6-week observation will be withdrawn from ABC-containing product and undergo EPT patch testing 6 weeks later.


Options:
A: Intervention Type: DRUG; Name: Abacavir; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Trizivir; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atazanavir; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combivir; Assigned to Arm(s): N/A
C: Arm Label: Trizivir (TZV) Arm; Type: EXPERIMENTAL; Interventions: Drug: Trizivir | Arm Label: Kaletra Arm; Type: EXPERIMENTAL; Interventions: Drug: Lamivudine/Zidovudine, Drug: Lopinavir/Ritonavir | Arm Label: Nevirapine (NVP) Arm; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine | Intervention Type: DRUG; Name: Trizivir; Assigned to Arm(s): Trizivir (TZV) Arm | Intervention Type: DRUG; Name: Lamivudine/Zidovudine; Assigned to Arm(s): Kaletra Arm | Intervention Type: DRUG; Name: Lopinavir/Ritonavir; Assigned to Arm(s): Kaletra Arm | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): Nevirapine (NVP) Arm
D: Arm Label: maternal nevirapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nevirapine | Arm Label: maternal placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: No intervention | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): maternal nevirapine | Intervention Type: DRUG; Name: No intervention; Assigned to Arm(s): maternal placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Controlled Randomized Trial of Circumferential Pulmonary Vein Ablation Versus Antiarrhythmic Drug Therapy in Treating Paroxysmal Atrial Fibrillation. The Ablation for Paroxysmal Atrial Fibrillation (APAF2) Trial
Brief Summary: Background: Circumferential pulmonary vein ablation (CPVA) has been safely and effectively performed for treating paroxysmal atrial fibrillation (PAF); however, its safety and efficacy, as compared with those of antiarrhythmic drug therapy (ADT), have never been formally assessed in a randomized controlled trial.

The Purpose of this study was to evaluate CPVA versus ADT in patients with PAF in a randomized controlled trial.


Options:
A: Arm Label: NAVISTAR® THERMOCOOL® Catheter; Type: EXPERIMENTAL; Interventions: Device: NAVISTAR® THERMOCOOL® Catheter | Arm Label: Antiarrhythmic drug; Type: ACTIVE_COMPARATOR; Interventions: Drug: Antiarrhythmic drug | Intervention Type: DEVICE; Name: NAVISTAR® THERMOCOOL® Catheter; Assigned to Arm(s): NAVISTAR® THERMOCOOL® Catheter | Intervention Type: DRUG; Name: Antiarrhythmic drug; Assigned to Arm(s): Antiarrhythmic drug
B: Intervention Type: PROCEDURE; Name: Circumferential Pulmonary Vein Ablation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Antiarrhythmic Drug Therapy; Assigned to Arm(s): N/A
C: Arm Label: Dronedarone 400mg bid; Type: EXPERIMENTAL; Interventions: Drug: Dronedarone (SR33589) | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Dronedarone (SR33589); Assigned to Arm(s): Dronedarone 400mg bid | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Dronedarone 400mg bid; Type: EXPERIMENTAL; Interventions: Drug: Dronedarone (SR33589) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Dronedarone (SR33589); Assigned to Arm(s): Dronedarone 400mg bid | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Controlled Randomized Trial of Circumferential Pulmonary Vein Ablation Versus Antiarrhythmic Drug Therapy in Treating Paroxysmal Atrial Fibrillation. The Ablation for Paroxysmal Atrial Fibrillation (APAF2) Trial
Brief Summary: Background: Circumferential pulmonary vein ablation (CPVA) has been safely and effectively performed for treating paroxysmal atrial fibrillation (PAF); however, its safety and efficacy, as compared with those of antiarrhythmic drug therapy (ADT), have never been formally assessed in a randomized controlled trial.

The Purpose of this study was to evaluate CPVA versus ADT in patients with PAF in a randomized controlled trial.


Options:
A: Intervention Type: PROCEDURE; Name: Circumferential Pulmonary Vein Ablation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Antiarrhythmic Drug Therapy; Assigned to Arm(s): N/A
B: Arm Label: Atrial Fibrillation Ablation; Type: EXPERIMENTAL; Interventions: Procedure: Atrial fibrillation ablation | Arm Label: Drug therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Antiarrhythmic drug | Intervention Type: PROCEDURE; Name: Atrial fibrillation ablation; Assigned to Arm(s): Atrial Fibrillation Ablation | Intervention Type: DRUG; Name: Antiarrhythmic drug; Assigned to Arm(s): Drug therapy
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Radiofrequency ablation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Radiofrequency ablation | Intervention Type: PROCEDURE; Name: Radiofrequency ablation; Assigned to Arm(s): 1, 2
D: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Device: Arctic Front® Cryoablation Catheter | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Flecainide or Sotalol or Propafenone | Intervention Type: DEVICE; Name: Arctic Front® Cryoablation Catheter; Assigned to Arm(s): Experimental | Intervention Type: DRUG; Name: Flecainide or Sotalol or Propafenone; Assigned to Arm(s): Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Controlled Randomized Trial of Circumferential Pulmonary Vein Ablation Versus Antiarrhythmic Drug Therapy in Treating Paroxysmal Atrial Fibrillation. The Ablation for Paroxysmal Atrial Fibrillation (APAF2) Trial
Brief Summary: Background: Circumferential pulmonary vein ablation (CPVA) has been safely and effectively performed for treating paroxysmal atrial fibrillation (PAF); however, its safety and efficacy, as compared with those of antiarrhythmic drug therapy (ADT), have never been formally assessed in a randomized controlled trial.

The Purpose of this study was to evaluate CPVA versus ADT in patients with PAF in a randomized controlled trial.


Options:
A: Intervention Type: DRUG; Name: CELIVARONE (SSR149744C); Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Radiofrequency ablation | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional treatment | Intervention Type: PROCEDURE; Name: Radiofrequency ablation; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Conventional treatment; Assigned to Arm(s): 2
C: Intervention Type: PROCEDURE; Name: Circumferential Pulmonary Vein Ablation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Antiarrhythmic Drug Therapy; Assigned to Arm(s): N/A
D: Arm Label: AF ablation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Atrial Fibrillation ablation | Arm Label: Amiodarone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amiodarone | Intervention Type: PROCEDURE; Name: Atrial Fibrillation ablation; Assigned to Arm(s): AF ablation | Intervention Type: DRUG; Name: Amiodarone; Assigned to Arm(s): Amiodarone

Answer: C